ProShares Ultra NASDAQ Biotechnology
11 hedge funds and large institutions have $3.58M invested in ProShares Ultra NASDAQ Biotechnology in 2013 Q4 according to their latest regulatory filings, with 6 funds opening new positions, 2 increasing their positions, 2 reducing their positions, and 2 closing their positions.
200% more first-time investments, than exits
New positions opened: 6 | Existing positions closed: 2
57% more funds holding
Funds holding: 7 → 11 (+4)
42% more capital invested
Capital invested by funds: $2.52M → $3.58M (+$1.06M)
0% more repeat investments, than reductions
Existing positions increased: 2 | Existing positions reduced: 2
100% less call options, than puts
Call options by funds: $0 | Put options by funds: $15K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PCM
Prelude Capital Management
New York
|
+$535K |
| 2 |
VKH
Virtu KCG Holdings
New York
|
+$438K |
| 3 |
VCAM
Valentine Capital Asset Management
Danville,
California
|
+$225K |
| 4 |
Jane Street
New York
|
+$205K |
| 5 |
GT
Glenmede Trust
Philadelphia,
Pennsylvania
|
+$16K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
LPL Financial
San Diego,
California
|
-$886K |
| 2 |
U
UBS
Zurich,
Switzerland
|
-$37.3K |
| 3 |
AIG
American International Group
New York
|
-$31.8K |
| 4 |
Creative Planning
Overland Park,
Kansas
|
-$25.4K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
1
LPL Financial
San Diego,
California
| $1.23M | -$886K | -26,508 | -45% |
|
|
PCM
2
Prelude Capital Management
New York
| $1.14M | +$535K | +16,000 | +112% |
|
|
VKH
3
Virtu KCG Holdings
New York
| $491K | +$438K | +13,096 | New |
|
|
VCAM
4
Valentine Capital Asset Management
Danville,
California
| $254K | +$225K | +6,740 | New |
|
|
5
Jane Street
New York
| $231K | +$205K | +6,128 | New |
|
|
GT
6
Glenmede Trust
Philadelphia,
Pennsylvania
| $161K | +$16K | +480 | +13% |
|
|
7
Creative Planning
Overland Park,
Kansas
| $35K | -$25.4K | -760 | -45% |
|
8
Morgan Stanley
New York
| $18K | +$16K | +480 | New |
|
|
S
9
SignatureFD
Atlanta,
Georgia
| $13K | – | – | – |
|
|
TCM
10
Tradewinds Capital Management
Bellingham,
Washington
| $5K | +$4.01K | +120 | New |
|
|
PFG
11
Piershale Financial Group
Barrington,
Illinois
| $3K | +$2.81K | +84 | New |
|
|
U
12
UBS
Zurich,
Switzerland
| – | -$37.3K | -1,116 | Closed |
|
|
AIG
13
American International Group
New York
| – | -$31.8K | -976 | Closed |
|
BIB Hedge Fund Activity: Q4 2013 in Review
11 of the 3,445 institutional investors tracked by Wall St. Rank reported a position in ProShares Ultra NASDAQ Biotechnology (BIB) for Q4 2013, worth a combined $3.58M — up 42% from $2.52M a quarter earlier.
Buyers outnumbered sellers: 6 funds opened new BIB positions and 2 closed out — a net gain of 4 holders — while 2 added to existing stakes and 2 trimmed.
The largest buyer was Prelude Capital Management, adding an estimated $535K. The largest seller was LPL Financial, cutting an estimated $886K.
- 11 institutional investors held ProShares Ultra NASDAQ Biotechnology (BIB) as of Q4 2013, up from 7 in Q3 2013.
- Funds reported $3.58M of ProShares Ultra NASDAQ Biotechnology stock for Q4 2013, up 42% quarter-over-quarter.
- 6 funds opened new ProShares Ultra NASDAQ Biotechnology positions in Q4 2013 and 2 closed out, a net change of +4 holders.
- The largest ProShares Ultra NASDAQ Biotechnology buyer in Q4 2013 was Prelude Capital Management, an estimated $535K added.
- The largest ProShares Ultra NASDAQ Biotechnology seller in Q4 2013 was LPL Financial, an estimated $886K sold.
Based on aggregated 13F filings for Q4 2013.